Standard usage and recommendation of aminoglycoside dosing regimens are 3, 6 and 15 mg/kg if the MIC of the infected organism is 1, 2 and 4 µg/ml, respectively. This dosing regimen is being followed for aminoglycosides such as gentamicin, netilmicin and tobramycin. Similarly, for amikacin 15 mg/kg is been preferred for MIC with 1 µg/ml and up to 30 mg/kg for an MIC of 2 µg/ml. [7, 8] However, recommendations for increased dosage is not certain, if the MIC of the infected organism is >2 µg/ml. The objectives of this study were to generate baseline MIC data for amikacin and gentamicin and to compare the in vitro susceptibility data with the current recommendations of dosing.
mateRIals and methods
Gram-negative bacilli causing intra-abdominal infections and urinary tract infections that met the criteria of significant pathogen were collected. One isolate per patient was included in this study. Isolates were received from seven hospitals across various regions of India. This includes, Christian Medical College, Vellore, Tamil Nadu; Hinduja Hospital, Mumbai; Manipal hospital, Bangalore, Karnataka; Fortis hospital, Kolkata, West Bengal; The Calcutta Medical Research Institute, Kolkata, West Bengal; Choithram hospital, Indore, Madhya Pradesh; and Sanjay Gandhi Post Graduate Institute of Medical Science, Lucknow, Uttar Pradesh. All the isolates were characterised up to species level by standard biochemical testing methods. [9] MIC were determined using Micro Scan dehydrated Broth Micro Dilution panels and the results were interpreted as per the CLSI and EUCAST guidelines. [10, 11] Amikacin was tested ranging from 4 to 32 µg/ml and gentamicin ranging from 1 to 16 µg/ml. Quality Control (QC) strains such as Escherichia coli ATCC 25922 and Pseudomonas aeruginosa ATCC 27853 were tested in each batch. Readings were taken if the QC range was satisfactory.
Results and dIscussIon
A total of 2326 Gram-negative bacilli that met with the inclusion criteria were collected during the period of 2013-2016 from seven different hospitals collected across India. For Amikacin, a total of 1957 isolates of Enterobacteriaceae and 228 isolates of P. aeruginosa were included and MIC was determined by broth micro dilution method. For Gentamicin, 62 isolates of Enterobacteriaceae and 79 isolates of non-fermenters were included and MIC was determined by VITEK 2 automated system. The results were interpreted according to CLSI guideline 2017. As per the CLSI guidelines, 79% of Enterobacteriaceae and 61% of P. aeruginosa were interpreted as susceptible to amikacin within MIC of ≤16 µg/ml, respectively. In contrast, as per the EUCAST guidelines, 72% of the Enterobacteriaceae isolates and 54% of the P. aeruginosa were interpreted susceptible with amikacin MIC of ≤8 µg/ml. Seven percent difference in the susceptibility was noted between CLSI and EUCAST interpretative criteria for Enterobacteriaceae and P. aeruginosa. The results discussed here are mentioned in Table 1 . Notably, the variations were due to the one tube dilution difference in the breakpoint recommended for interpreting susceptibility by CLSI and EUCAST. While, two-fold dilution difference was noticed in the breakpoints for interpreting the isolates as resistant. The clinical breakpoint values are mentioned in Table 2 .
When comparing in vitro MIC data with CLSI cut-off, for amikacin, 79% of the Enterobacteriaceae isolates were susceptible with MIC of ≤16 µg/ml. However, only 55% were actually treatable with MIC of ≤4 µg/ml as per the current dosing regimen. This is due to the C max of the serum drug concentration, which can be effective with MIC of ≤4 µg/ml. Although 24% of the bacterial isolates are clinically susceptible with MIC of 8-16 µg/ml, administration of standard dosing regimen (15 mg/kg) would not achieve sufficient drug concentration in the serum for the bactericidal effect. This leads to the under dosing and likely show a poor clinical outcome if the MIC of an infected organism is 8-16 µg/ml, which is defined as susceptible based on laboratory testing. Similarly, for P. aeruginosa, huge difference was noted in the susceptible isolates with less chance for clinical success. Although 61% of the isolates were susceptible, only 36% of the isolates had an MIC of ≤4 µg/ml, while 25% had an MIC 8-16 µg/ml, respectively.
While with the EUCAST cut-off, 20% difference was noted between the MIC that can be clinically treatable with adequate serum concentration for bacterial isolates MIC within the susceptible range, but likely to show poor clinical response. For aminoglycosides, EUCAST interpretative criteria seem to be a better option than CLSI. However, caution should be exercise that the method followed for aminoglycoside MIC determination is also by the EUCAST. Mismatching of CLSI testing method and EUCAST interpretative criteria must be avoided. To the best of our knowledge, this is the first study comparing in vitro susceptibility data with the clinical dosing parameters, to substantiate the inadequate serum concentration (C max /MIC) resulting in poor clinical outcome. This urges the need for optimising the dose prescribed for amikacin based on the MIC value to improve the clinical response. Moreover, to avoid inappropriate or under dosing that might leads to development of resistance. Further, clinical trials warrants the toxicity issues associated with increased dosage.
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